The Oncosearch | Oncotarget

Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials Research Paper

Maryam Aleid, Fatimah Aleid, Daniah Allbdi, Ahmad Rchdeih, Dhai Almuteri, Abdulelah Almesned, Samaa Alotab, Yumna AlMishary, Galia Alsamman, Atlal Abusanad

Published Apr 1, 2026 · Vol. 17, No. 1 · pp. 120-135

Keywords: PD-1, PD-L1, adjuvant immunotherapy, cancer, solid tumor

Correction: Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells Correction

Steven A. Greenberg

Published Mar 20, 2026 · Vol. 17, No. 1 · pp. 57-58

ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response Research Paper

Kyle R. Cron, Ping Fang, Oanh Pham, Julie Janes, John Brandenburg, William Lu, Jonathan Zhu, Bret Peterson, Sara Tribble, Haixing Kehoe, Anastasia Makarova, Alex Iannello, Jean Chan, Justin Skoble, Hailey He, Chris Rae, Christopher D. Thanos, Akshata R. Udyavar

Published Oct 2, 2025 · Vol. 16, No. 1 · pp. 721-740

Keywords: tumor microenvironment, bacterial vector, myeloid cells, STING, IL-15

Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights Research Paper

Cleto Dantas Nogueira, Samuel Frota, Huylmer Lucena Chaves, Juliana Cordeiro de Sousa, Guilherme de Sousa Veloso, Francisco Jonathan dos Santos Araujo, Gabriel Barbosa Silva, Samuel Silva Ferreira, Marclesson Santos Alves, Fabio Nasser, Ezequiel Rangel, Francisco Martins Neto, Iusta Caminha, Ellen Nascimento, Fabio Tavora

Published May 31, 2025 · Vol. 16, No. 1 · pp. 467-479

Keywords: HER2 mutation, NSCLC, lung cancer, targeted therapy, genomic profiling

Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy Review

Nazmul Hasan, Daniel Yang, Spencer Gibson, Barbod Khaleghi, Rozhan Ziari, Arash Rezazadeh Kalebasty

Published May 8, 2025 · Vol. 16, No. 1 · pp. 337-346

Keywords: bladder cancer, immunotherapy, radiation, microenvironment, abscopal

PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region Research Paper

Humberto Carvalho Carneiro, Rodrigo de Andrade Natal, José Vassallo, Fernando Augusto Soares

Published Apr 21, 2025 · Vol. 16, No. 1 · pp. 277-290

Keywords: HPV, high-grade intraepithelial lesion, immune evasion, PD-L1, FOXP3

Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells Research Paper

Steven A. Greenberg

Published Jan 7, 2025 · Vol. 16, No. 1 · pp. 1-8

Keywords: immunotherapy, KLRG1

Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors Mini-Review

Joshua J. Lingo, Ellen Voigt, Dawn E. Quelle

Published Sep 19, 2024 · Vol. 15, No. 1 · pp. 638-643

Keywords: MPNST, FOXM1, PD-L1, CDK4/6-MEK targeting, therapy resistance

Starving cancer cells to enhance DNA damage and immunotherapy response Research Perspective

Aashirwad Shahi, Dawit Kidane

Published Jun 12, 2024 · Vol. 15, No. 1 · pp. 392-399

Keywords: amino acid depletion, DNA damage, DNA repair, Immunotherapy, tumor immunity

Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma Research Paper

Kazuhiro Kitajima, Kozo Kuribayashi, Toshiyuki Minami, Hiroyuki Yokoyama, Akifumi Nakamura, Masaki Hashimoto, Takashi Kijima, Seiki Hasegawa, Hayato Kaida, Koichiro Yamakado

Published Jun 11, 2024 · Vol. 15, No. 1 · pp. 408-417

Keywords: mesothelioma, immunotherapy, FDG (fluorodeoxyglucose), PET-CT (positron emission tomography-computed tomography), immunotherapy-modified PERCIST (positron emission tomography response criteria in solid tumors)

GZ17-6.02 kills PDX isolates of uveal melanoma Research Paper

Laurence Booth, Jane L. Roberts, Ivan Spasojevic, Kaitlyn C. Baker, Andrew Poklepovic, Cameron West, John M. Kirkwood, Paul Dent

Published May 9, 2024 · Vol. 15, No. 1 · pp. 328-344

Keywords: autophagy, ER stress, GZ17-6.02, doxorubicin, afatinib, neratinib

Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer Research Paper

Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, Khoi Chu, Akshara Singareeka Raghavendra, Clinton Yam, Lumarie Santiago, Beatriz E. Adrada, Padmanee Sharma, Elizabeth A. Mittendorf, Jennifer K. Litton

Published Mar 2, 2024 · Vol. 15, No. 1 · pp. 238-247

Keywords: breast cancer, ER positive, immunotherapy, neoadjuvant chemotherapy, tumor microenvironment

Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells Correction

Yunfei Liao, Lulu Chen, Yong Feng, Jacson Shen, Yan Gao, Gregory Cote, Edwin Choy, David Harmon, Henry Mankin, Francis Hornicek, Zhenfeng Duan

Published Nov 21, 2023 · Vol. 15, No. 1 · pp. 104-105

Addendum: Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver Addendum

Marta Domènech, Ana M. Muñoz Marmol, Jose Luis Mate, Anna Estival, Teresa Moran, Marc Cucurull, Maria Saigi, Ainhoa Hernandez, Carolina Sanz, Alba Hernandez-Gallego, Aintzane Urbizu, Anna Martinez-Cardus, Adrià Bernat, Enric Carcereny

Published Aug 30, 2023

Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies Review

Meghali Goswami, Jeffrey Schlom, Renee N. Donahue

Published Aug 3, 2023 · Vol. 14, No. 1 · pp. 758-774

Keywords: HPV-associated malignancies, immunotherapy, circulating tumor DNA, circulating tumor cells, HPV-specific antibodies

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma Addendum

Eduard Teixidor, Elia Sais, Carmen Amalia Vásquez, Walter Carbajal, Alejandro Hernández, Gloria Sánchez, Angel Izquierdo, Sara Verdura, Javier A. Menéndez, Joaquim Bosch-Barrera

Published Jun 27, 2023 · Vol. 14, No. 1 · pp. 668-668

Targeting GITR in cancer immunotherapy – there is no perfect knowledge Research Perspective

Diwakar Davar, Roberta Zappasodi

Published Jun 12, 2023 · Vol. 14, No. 1 · pp. 614-621

Keywords: cancer, immunotherapy, programmed death-1 (PD-1), cytotoxic T-lymphocyte Antigen-4 (CTLA-4), glucocorticoid-induced TNFR-related protein (GITR)

Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss Research Paper

Maroun Bou Zerdan, Prashanth Ashok Kumar, Elio Haroun, Nimisha Srivastava, Jeffrey Ross, Abirami Sivapiragasam

Published Feb 25, 2023 · Vol. 14, No. 1 · pp. 178-187

Keywords: breast cancer, metastatic, MTAP loss

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) Research Paper

Leo I. Gordon, Reem Karmali, Jason B. Kaplan, Rakesh Popat, Howard A. Burris III, Silvia Ferrari, Sumit Madan, Manish R. Patel, Giuseppe Gritti, Dima El-Sharkawi, F. Ian Chau, John Radford, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Swaminathan P. Iyer, William Townsend, Harry Miao, Igor Proscurshim, Shining Wang, Shilpi Katyayan, Ying Yuan, Jiaxi Zhu, Kate Stumpo, Yaping Shou, Cecilia Carpio, Francesc Bosch

Published Jan 20, 2023 · Vol. 14, No. 1 · pp. 57-70

Keywords: Non-Hodgkin’s lymphoma, DLBCL, relapsed/refractory, SYK inhibitor, TAK-659

Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression Research Paper

Hongyan Yuan, Lu Jin, Handan Xiang, Anannya Bhattacharya, Philip E. Brandish, Gretchen Baltus, Alexander Tong, Changyan Zhou, Robert I. Glazer

Published Dec 10, 2022 · Vol. 13, No. 1 · pp. 1350-1358

Keywords: PD-1, NeuT, Wnt, macrophages, mammary tumorigenesis

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials Research Paper

Correction: Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells Correction

ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response Research Paper

Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights Research Paper

Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy Review

PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region Research Paper

Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells Research Paper

Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors Mini-Review

Starving cancer cells to enhance DNA damage and immunotherapy response Research Perspective

Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma Research Paper

GZ17-6.02 kills PDX isolates of uveal melanoma Research Paper

Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer Research Paper

Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells Correction

Addendum: Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver Addendum

Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies Review

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma Addendum

Targeting GITR in cancer immunotherapy – there is no perfect knowledge Research Perspective

Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss Research Paper

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) Research Paper

Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials Research Paper

Correction: Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells Correction

ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response Research Paper

Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights Research Paper

Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy Review

PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region Research Paper

Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells Research Paper

Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors Mini-Review

Starving cancer cells to enhance DNA damage and immunotherapy response Research Perspective

Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma Research Paper

GZ17-6.02 kills PDX isolates of uveal melanoma Research Paper

Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer Research Paper

Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells Correction

Addendum: Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver Addendum

Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies Review

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma Addendum

Targeting GITR in cancer immunotherapy – there is no perfect knowledge Research Perspective

Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss Research Paper

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) Research Paper

Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression Research Paper